Cargando…
Will (177)Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration
Somatostatin receptor subtype 2 upregulation is very common in meningiomas, and the use of peptide receptor radionuclide therapy (PRRT) is recognized in recent European guidelines, with long-term stable disease and a long overall survival. Treatment efficacy of radionuclide treatments is correlated...
Autores principales: | Braat, A. J. A. T., Snijders, T. J., Seute, T., Vonken, E. P. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775534/ https://www.ncbi.nlm.nih.gov/pubmed/31187231 http://dx.doi.org/10.1007/s00270-019-02262-1 |
Ejemplares similares
-
Somatostatin receptor saturation after administration of high peptide amounts of [(177)Lu]Lu-HA-DOTATATE: when enough is enough
por: Siebinga, Hinke, et al.
Publicado: (2022) -
Efficacy of (177)Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma
por: Zahid, Anza, et al.
Publicado: (2021) -
Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020) -
(177)Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
por: Kumar Jaiswal, Sanjeet, et al.
Publicado: (2020) -
Upregulation of Somatostatin Receptor Type 2 Improves (177)Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
por: Sharma, Rupali, et al.
Publicado: (2023)